D.E. Shaw & Co
BTAI icon

D.E. Shaw & Co’s BioXcel Therapeutics BTAI Stock Holding History

D.E. Shaw & Co’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,647
Closed -$125K – 4362
2023
Q4 		$125K Buy
+2,647
New +$147K ﹤0.01% 3947
2020
Q3 		– Sell
-1,190
Closed -$1.01M – 3851
2020
Q2 		$1.01M Buy
+1,190
New +$776K ﹤0.01% 2923

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's BTAI Position: Q1 2024 in Review

D.E. Shaw & Co sold out of BioXcel Therapeutics (BTAI) in Q1 2024, closing a stake of 2,647 shares — an estimated $125K sold.

D.E. Shaw & Co first reported a position in BTAI in Q2 2020 and held it in 2 quarters. The position peaked at $1.01M in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

  • D.E. Shaw & Co reported no remaining BioXcel Therapeutics position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 2,647 BioXcel Therapeutics shares in Q1 2024, an estimated $125K.
  • D.E. Shaw & Co first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 2 quarters.
  • D.E. Shaw & Co's BioXcel Therapeutics position peaked at $1.01M in Q2 2020.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.